Elizabeth L. Lockerman
Harvard University(US)Massachusetts General Hospital(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer therapeutics and mechanisms, Melanoma and MAPK Pathways, Lung Cancer Research Studies
Most-Cited Works
- → Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer(2016)1,131 cited
- → Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition(2016)978 cited
- → The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer(2014)837 cited
- → Patient-derived models of acquired resistance can identify effective drug combinations for cancer(2014)731 cited
- → RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer(2015)626 cited
- → The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies(2015)543 cited
- → Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor(2015)460 cited
- → CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors(2014)432 cited
- → Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1(2013)410 cited
- → Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF -Mutant Colorectal Cancer through MAPK Pathway Alterations(2015)316 cited